Epigenetic therapy by artificial chromatin remodeling
| Project/Area Number |
25560227
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Tokyo Metropolitan University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | エピジェネティクスジェネティクス / クロマチン / エピゲノム創薬 / 細胞分化治療 / エピジェネティクス |
|---|
| Outline of Final Research Achievements |
In this study, we have designed epigenetics control carrier (EpC carrier) as a novel method to control histone acetylation by the synergistic effect of gene transfection and inhibitors (Fig. 1B). If we could establish the method, it is expected that control for cell differentiation and treatment of diseases will become possible by returning to original state of the epigenome. The resulting epigenetics engineering can be a treatment of intractable diseases. We demonstrated that EpC carrier enhances the acetylation amount and the cell differentiation ratio by the synergistic effect and the biodegradability.
|
Report
(3 results)
Research Products
(9 results)
